<DOC>
	<DOCNO>NCT01431937</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , pharmacokinetics pharmacodynamics repeat ascend dos GSK2018682 . The study also provide evidence potential therapeutic dose-range measure inhibitory effect GSK2018682 Absolute Lymphocyte Counts ( ALC ) .</brief_summary>
	<brief_title>Assessment Repeat Ascending Doses GSK2018682 Healthy Volunteers</brief_title>
	<detailed_description>The study evaluate safety , tolerability , pharmacokinetics pharmacodynamics repeat ascend dos GSK2018682 . The study also provide evidence potential therapeutic dose-range measure inhibitory effect GSK2018682 Absolute Lymphocyte Counts ( ALC ) .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Females must nonchildbearing potential . BMI within range 19 29 kg/m2 ( inclusive ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Were participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Unwillingness inability follow procedure outline protocol . Other exclusion criterion detailed time physical screening Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>